Investor Presentations
Renalytix plc announced upcoming investor engagement opportunities, including a live online presentation via Investor Meet Company on September 29, 2026, and participation in the MelloLondon2026 event on November 17, 2026. The company, focused on precision medicine diagnostics for kidney disease, will provide updates on its KidneyIntelX technology and commercial offerings. These presentations aim to inform existing and potential shareholders about the company's progress and strategic direction.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 25 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that it will host a live online investor presentation next week and will be presenting at the MelloLondon2026 event in November. Details of the two events are below.
On-line presentation: Investor Meet Company
James McCullough, Chief Executive Officer, will provide a live presentation via Investor Meet Company at 16:00 BST on Tuesday, 29 September 2026. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Renalytix Plc via:
Investors who already follow Renalytix plc on the Investor Meet Company platform will automatically be invited.
In-person presentation: MelloLondon2026
Renalytix will also be presenting at the MelloLondon2026 investor event on Tuesday 17 November 2026. The event is taking place at The Clayton Hotel & Conference Centre, Chiswick High Road, London, W4 5RY.
Renalytix will present twice during the event. There will also be opportunity to interact with the management team at the Company’s exhibitor stand. For further information and tickets for the MelloLondon2026 conference, please visit the event website at https://www.melloevents.com/mellolondon2026.
RenalytixTM (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company dedicated to optimizing kidney disease management through precision-based care intervention. It’s KidneyIntelX™ technology and data-driven insights help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. This enables clinicians to focus resources and guideline-recommended treatment, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.
RenalytixTM has been granted FDA authorization and Medicare reimbursement for kidneyintelX.dkd which is offered commercially throughout the United States. For more information about the kidneyintelX.dkd test, visit www.kidneyintelx.com.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.